What Is a Lesion in the Breast & What Does It Mean?

A breast lesion is any area of abnormal tissue in the breast, and the term covers everything from a harmless fluid-filled cyst to an early-stage cancer. Hearing the word “lesion” on a radiology report can be alarming, but the label itself carries no diagnosis. It simply means imaging or a physical exam picked up something that looks different from the surrounding breast tissue. The vast majority of breast lesions turn out to be benign, though some sit in a gray zone that requires closer monitoring or a biopsy to sort out.

Why Doctors Use the Word “Lesion”

In medical imaging, “lesion” is deliberately vague. Radiologists use it as a placeholder until they have more information, because the same shadow on a mammogram could be a cyst, a cluster of calcium deposits, scar tissue from a previous surgery, or a tumor. The American College of Radiology developed a standardized vocabulary called BI-RADS (Breast Imaging Reporting and Data System) specifically so radiologists describe what they see in consistent terms: masses, foci, areas of non-mass enhancement, and so on.¹ A BI-RADS category from 0 (needs more imaging) to 6 (known cancer) is then assigned to help your clinical team decide what to do next. Getting a report that says “breast lesion, BI-RADS 3” is very different from “breast lesion, BI-RADS 5,” even though both use the same word.

Benign Lesions and What They Look Like

Most breast lesions fall squarely into the benign category. Cysts are among the most common: fluid-filled sacs that form when the small ducts in the breast become dilated. On ultrasound, a simple cyst appears as a round, dark (anechoic) area with sharp borders, and it is classified as BI-RADS 2, meaning benign and requiring no further workup.² A complicated cyst, which contains some internal debris but otherwise meets the same criteria, is typically rated BI-RADS 3 (probably benign) and may be rechecked in six months. Complex cystic and solid masses, which contain both fluid and a solid component, usually warrant a biopsy because the malignancy rate is higher.³

Fibroadenomas are another extremely common benign finding, particularly in younger women. They are solid, rubbery masses made up of both glandular and connective tissue, and they tend to be well-defined on imaging. Fibrocystic changes, a broad term for lumpy or ropy breast tissue driven by normal hormonal fluctuations, can sometimes form a focal mass that mimics cancer on MRI.⁴ Estrogen plays a central role in many of these benign conditions, influencing cell growth and proliferation in breast tissue.⁵

Fat Necrosis and Other Mimics

One of the trickiest benign lesions is fat necrosis, an inflammatory reaction that occurs when fatty tissue in the breast is damaged, often after surgery, radiation, or even a seatbelt injury. The reason it causes so much anxiety is that it can look remarkably similar to cancer on a mammogram or MRI, producing irregular masses, spiculated borders, or suspicious calcifications.⁶ Radiologists who recognize the wide spectrum of fat necrosis appearances can sometimes avoid an unnecessary biopsy, but when the imaging is ambiguous, tissue sampling is the safest path.⁷

The Gray Zone Between Benign and Cancerous

Some lesions are not cancer themselves but signal a higher-than-average chance of developing cancer in the future. Radiologists and pathologists often refer to these as “high-risk” or “proliferative” lesions. Two of the most discussed are atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH). In ADH, cells lining the breast ducts are growing in an abnormal pattern but have not crossed the line into carcinoma. A large study found that within ten years of an ADH diagnosis, roughly 6 percent of women developed invasive breast cancer, compared with about 2 percent of women without ADH.⁸ A meta-analysis looking at multiple high-risk lesion types estimated that at ten years, the cumulative breast cancer incidence was roughly 12 percent for lobular carcinoma in situ, about 14 percent for ADH, and around 15 percent for ALH.⁹ Those numbers sound high, but they also mean the majority of women with these findings never develop cancer. The key is closer surveillance and, in some cases, risk-reducing medication.

Radial scars are another proliferative finding that raises eyebrows. These star-shaped growths of fibrous and glandular tissue can look worrisome on imaging, and women with radial scars had roughly double the breast cancer risk compared with women without them.¹⁰ When a radial scar was found alongside other proliferative changes, the combined risk climbed higher still. Historically, radial scars discovered on a needle biopsy were sent for surgical excision, but the upstage rate from a pure radial scar to malignancy is low, around 1 percent in one recent series.¹¹ This has led some centers to consider surveillance rather than automatic surgery for select patients.

In Situ Carcinomas

Ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) occupy an unusual space: the cells look cancerous under a microscope, but they have not invaded beyond the duct or lobule where they started. DCIS is more common and is usually treated as an early-stage cancer, often with surgery and sometimes radiation, because a meaningful fraction of untreated DCIS can progress to invasive disease. LCIS, meanwhile, is treated more as a risk marker for future cancer in either breast. Risk factors for both overlap substantially, though long-term use of hormone replacement therapy showed a stronger association with LCIS than with DCIS.¹²

Invasive Breast Cancer

When a lesion does turn out to be malignant and has grown beyond the duct or lobule walls into surrounding tissue, it is classified as invasive. Invasive ductal carcinoma (IDC) is the most common type, making up the majority of breast cancers. Invasive lobular carcinoma (ILC) is less frequent but tends to present differently: patients with ILC are often older at diagnosis, have lower-grade tumors but larger tumor sizes, and are more likely to have estrogen-receptor-positive disease and less likely to overexpress HER2.¹³ Treatment planning for any invasive cancer now hinges on biomarker testing of the tumor tissue, including estrogen receptor (ER), progesterone receptor (PR), and HER2 status. Biopsy samples tested for these markers match the final surgical specimen with concordance rates above 90 percent, giving oncologists reliable information before surgery even takes place.¹⁴

How Lesions Are Found

Most breast lesions are discovered through one of three imaging methods: mammography, ultrasound, or MRI. Mammography is the workhorse of screening and catches the majority of abnormalities in average-risk women. But it has blind spots. In dense breast tissue, where fibrous and glandular tissue obscures potential masses, mammography performs less well. Ultrasound excels at differentiating solid from cystic lesions and is particularly useful in younger women and as a follow-up to a mammographic finding. MRI offers the highest sensitivity and is generally reserved for high-risk screening or problem-solving, though it tends to produce slightly more false positives, which means more callbacks and biopsies for findings that ultimately prove benign.¹⁵ No single modality is best for everyone. Clinicians combine imaging tools based on your age, breast density, risk factors, and the specific question they are trying to answer.¹⁶

Biopsy and What Happens After

When imaging cannot definitively rule out something worrisome, the next step is usually a needle biopsy. Two main types dominate: core needle biopsy (CNB) and vacuum-assisted breast biopsy (VABB). Both use a hollow needle guided by imaging to extract tissue samples, but VABB retrieves larger samples in a single pass. That distinction matters because larger samples are less likely to “underestimate” a lesion, meaning the biopsy result is less likely to miss a more serious finding that only shows up in a bigger piece of tissue. A meta-analysis found that VABB significantly reduced the underestimation rate for both ADH and DCIS compared with standard core needle biopsy, and also lowered the rate of repeat biopsies.¹⁷ In one study focused specifically on DCIS, the underestimation rate dropped from about 48 percent with a standard 14-gauge core needle to roughly 16 percent with vacuum-assisted biopsy.¹⁸

After biopsy, the pathology results are cross-checked against the imaging findings in a process called radiologic-pathologic concordance. If the biopsy shows benign tissue and the imaging looked benign, everyone agrees and routine follow-up is appropriate. Discordance, where the biopsy result does not match what the imaging suggested, triggers further action. In one large series of MRI-guided vacuum-assisted biopsies, about 2 percent of results were discordant, and more than a third of those discordant cases turned out to be malignant at surgical excision.¹⁹ Many hospitals now hold multidisciplinary conferences where radiologists and pathologists review these cases together, because catching a discordant result early can change outcomes.²⁰

When Surgery May Not Be Automatic

Traditionally, any high-risk finding on a needle biopsy, especially ADH, meant automatic surgical excision to make sure nothing worse was lurking nearby. That practice is evolving. Risk calculators can now stratify patients with ADH into groups, and one validated tool identified a cohort with only about a 2 percent chance of being upstaged to carcinoma at surgery.²¹ For those patients, close imaging surveillance may eventually become an acceptable alternative to the operating room, though this approach is still being studied and is not yet standard of care everywhere.

Breast Lesions in Men

Breast lesions are not exclusively a concern for women. Men have breast tissue too, and the overwhelming majority of male breast masses are benign. Gynecomastia, a hormonally driven enlargement of glandular tissue beneath the nipple, is by far the most common finding.²² It typically presents as a soft, mobile mass under the areola and can be caused by medications, obesity, liver disease, or natural hormonal shifts. Its imaging appearance is characteristic enough that radiologists can usually distinguish it from malignancy without a biopsy.²³ Primary breast cancer in men accounts for less than 1 percent of all breast cancers, but it does occur, and when a male breast mass has features that depart from the typical gynecomastia pattern, such as an eccentric location, skin dimpling, or nipple retraction, imaging and biopsy follow a similar pathway as in women.²⁴

Breast Lesions in Children and Adolescents

Finding a breast lump in a child or teenager is understandably frightening for families, but the picture here is overwhelmingly reassuring. Nearly all breast masses in the pediatric and adolescent population are benign or related to normal development. Fibroadenomas are the most common solid mass in this age group.²⁵ Biopsy and surgery are approached more cautiously in young patients because interventional procedures can potentially damage the developing breast bud. When malignancy does occur in this group, it tends to be a secretory type with less metastatic potential than adult breast cancers, though aggressive subtypes have been reported.²⁶

Lesions Found During Pregnancy and Breastfeeding

Pregnancy and lactation transform the breast dramatically: ducts enlarge, glandular tissue proliferates, and overall blood flow increases. These physiological changes can make new lumps harder to evaluate and existing lumps easier to miss. Lactating adenomas, galactoceles (milk-filled cysts), and abscesses are common benign findings during this period. Radiologists familiar with the normal imaging appearance of pregnancy-related changes can more confidently distinguish them from suspicious lesions.²⁷ Ultrasound is the preferred first-line imaging tool during pregnancy because it avoids radiation. Mammography can be performed with shielding if necessary, and MRI without contrast is considered safe, though gadolinium-based contrast agents are generally avoided during pregnancy.

The Growing Role of Artificial Intelligence

Artificial intelligence is starting to change how breast lesions are detected and categorized. Deep-learning algorithms trained on thousands of mammograms and ultrasound images can flag suspicious areas, assist with BI-RADS classification, and even help predict whether a lesion is likely benign or malignant. A systematic review found that AI consistently performed at least as well as radiologists in detecting breast lesions, with additional benefits like shorter reading times and improved triage efficiency.²⁸ In practice, AI is not replacing radiologists but functioning as a second set of eyes, catching findings that a busy reader might overlook and helping prioritize which studies need urgent attention. The technology is still being refined, and regulatory oversight of these tools continues to evolve, but the trajectory suggests AI will become a routine part of breast imaging workflows within the next decade.²⁹

How Tumor Subtyping Guides Treatment

When a breast lesion does prove to be cancer, the biopsy tissue undergoes further testing that shapes the entire treatment plan. Pathologists check for estrogen and progesterone receptors and HER2 protein. These markers, combined with a proliferation marker called Ki-67, allow the tumor to be sorted into molecular subtypes: luminal A, luminal B, HER2-enriched, or triple-negative.³⁰ The subtype matters enormously. Hormone-receptor-positive cancers can be treated with drugs that block estrogen’s effects, often avoiding the most aggressive chemotherapy regimens. HER2-positive tumors respond to targeted therapies that have dramatically improved survival over the past two decades. Triple-negative cancers, which lack all three receptors, tend to be more aggressive and have fewer targeted options, though immunotherapy is expanding the toolkit. The point is that two breast cancers that look identical on a mammogram may require completely different treatments once their molecular profiles are known.